Search
FDA Approves Rituxan-Chemotherapy Combo for Children with a Variety of Blood Cancers
- OPACC
- Dec 10, 2021
- 1 min read
The FDA approval of Rituxan plus chemotherapy is indicated for the treatment of children aged six months to 18 years who have various forms of lymphoma or a form of leukemia.
Recent Posts
See AllQuality of life improvements can be made if clinicians better understand auditory attention decay after cancer treatment in pediatric...
A team of experts, issuing a statement on behalf of the American Heart Association, have detailed cardiometabolic considerations for...
While the overall prevalence of comorbidities at diagnosis in pediatric patients with acute lymphoblastic leukemia (ALL) and...
Comments